 |
 |
Dacetuzumab (SGN-40) is a humanized monoclonal antibody that targets the CD40 antigen, which is expressed on most B lineage hematologic malignancies, as well as some solid tumors.
For more detailed information about the clinical trials summarized below, click on the link to the trial listing at www.clinicaltrials.gov.
Single-arm trial evaluating safety
and activity of dacetuzumab in combination with Rituxan
(rituximab) and Gemzar (gemcitabine) for relapsed and
refractory diffuse large B-cell lymphoma
Enrollment to
this trial is complete.
Single-arm trial evaluating safety and activity of dacetuzumab in combination with Rituxan (rituximab) for relapsed and refractory indolent non-Hodgkin lymphoma, including follicular lymphoma
Enrollment to this trial is complete.
Single-arm trial evaluating safety
and activity of dacetuzumab in combination with Revlimid
(lenalidomide) for relapsed and refractory multiple
myeloma
Enrollment to this trial is complete.
Single-arm trial evaluating safety and activity of dacetuzumab in combination with Velcade (bortezomib)
for relapsed and refractory multiple myeloma
Enrollment
to this trial is complete.
If you have questions about the dacetuzumab clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma, multiple myeloma and participating in clinical trials can be found on the following web sites.